For the Inventor, By the Inventor

Enter assignee name

London, United Kingdom

Intrabio Limited

Calculating rank

USPTO Granted Patents = 18

EPO Patents = 11

Trademarks = 1

Forward Citations = 45

Loading Chart...

Loading Chart...

4 inventors (with patents filed for the assignee):

Michael Strupp (14 out of 14 patents)

Mallory Factor (8 out of 8 patents)

Michiko Mann (1 out of 1 patent)

4. Grant Charles Churchill (1 out of 1 patent)

5. Taylor Fields (0 patent)

18 patents: Sort by Forward Citations

1. 12715839 - Branched-chain amino acid derivatives to treat disease (2026-08-25),

2. 12697316 - Combination therapy with acetyl-leucine and miglustat (2026-08-04),

3. 12667550 - Treatment of late-onset neurodegenerative diseases in heterozygous NPC1 gene mutation carriers (2026-06-30),

4. 12458614 - Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders (2025-11-04),

5. 12433863 - Pharmaceutical compositions and uses directed to lysosomal storage disorders (2025-10-07),

6. 12433862 - Pharmaceutical compositions and uses directed to lysosomal storage disorders (2025-10-07),

7. 12329733 - Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function (2025-06-17),

8. 12145899 - Deuterated analogs of acetyl-leucine (2024-11-19),

9. 12144792 - Therapeutic agents for neurodegenerative diseases (2024-11-19),

10. 12121513 - Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject (2024-10-22),

11. 11998518 - Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function (2024-06-04),

12. 11793782 - Therapeutic agents for neurodegenerative diseases (2023-10-24),

13. 11690830 - Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject (2023-07-04),

14. 11660279 - Therapeutic agents for treating restless leg syndrome (2023-05-30),

15. 11471434 - Treatment for migraine (2022-10-18),

Company Overview

Intrabio Limited is a biotechnology company based in London, specializing in the development of innovative therapies for neurodegenerative diseases. The organization focuses on advancing treatments that target the underlying mechanisms of these conditions, aiming to improve patient outcomes and quality of life. With a commitment to scientific excellence, Intrabio leverages cutting-edge research and technology to address unmet medical needs in the field of neurology, contributing to the broader landscape of healthcare advancements.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

18 Patents

#206 in London

#1,001 in United Kingdom

#34,244 in the World

London, United Kingdom

Intrabio Limited

Forward Citations = 45

4 inventors:

Michael Strupp (14 out of 14 patents)

Mallory Factor (8 out of 8 patents)

Michiko Mann (1 out of 1 patent)

4. Grant Charles Churchill (1 out of 1 patent)

5. Taylor Fields (0 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Intrabio Limited. Retrieved from https://idiyas.com/company/intrabio

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…